1. Home
  2. SPIR vs DSGN Comparison

SPIR vs DSGN Comparison

Compare SPIR & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spire Global Inc.

SPIR

Spire Global Inc.

HOLD

Current Price

$11.60

Market Cap

826.5M

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$12.27

Market Cap

853.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPIR
DSGN
Founded
2012
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
826.5M
853.8M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
SPIR
DSGN
Price
$11.60
$12.27
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
4
Target Price
$16.40
$15.25
AVG Volume (30 Days)
502.5K
598.0K
Earning Date
05-13-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
134.98
N/A
EPS
N/A
N/A
Revenue
$110,451,000.00
N/A
Revenue This Year
$12.31
N/A
Revenue Next Year
$22.63
N/A
P/E Ratio
N/A
N/A
Revenue Growth
13.15
N/A
52 Week Low
$6.60
$5.28
52 Week High
$25.93
$17.25

Technical Indicators

Market Signals
Indicator
SPIR
DSGN
Relative Strength Index (RSI) 35.65 36.89
Support Level $10.30 $9.78
Resistance Level $15.07 $13.54
Average True Range (ATR) 0.66 0.65
MACD -0.16 -0.23
Stochastic Oscillator 10.40 3.56

Price Performance

Historical Comparison
SPIR
DSGN

About SPIR Spire Global Inc.

Spire Global Inc provides space-based data, analytics, and space services, offering datasets and insights about Earth to support decision-making. It builds, owns, and operates a constellation of nanosatellites that observe the Earth in real time using radio frequency (RF) technology. Additionally, it offers Space Services solutions that allow customers to deploy and scale their own satellite constellations using its platform, ground station network, manufacturing facilities, and launch partnerships. The company derives revenue from providing data, insights and access to its cloud-based technology platform sold on a subscription basis.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: